[1] Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2022, 7:851-861.
[2] Virtue S, Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biol, 2008, 6:e237.
[3] Xia W, Pessentheiner AR, Hofer DC, et al. Loss of ABHD15 Impairs the Anti-lipolytic Action of Insulin by Altering PDE3B Stability and Contributes to Insulin Resistance. Cell reports, 2018, 23:1948-1961.
[4] Schweiger M, Romauch M, Schreiber R, et al. Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice. Nat Commun, 2017, 8:14859.
[5] Softic S, Boucher J, Solheim MH, et al. Lipodystrophy Due to Adipose Tissue-Specific Insulin Receptor Knockout Results in Progressive NAFLD. Diabetes, 2016, 65:2187-2200.
[6] Montagner A, Polizzi A, Fouché E, et al. Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut, 2016, 65:1202-1214.
[7] Zhao S, Zhu Y, Schultz RD, et al. Partial Leptin Reduction as an Insulin Sensitization and Weight Loss Strategy. Cell Metabol, 2019, 30:706-719.e706.
[8] Tang X, Li J, Xiang W, et al. Metformin increases hepatic leptin receptor and decreases steatosis in mice. J Endocrinol, 2016, 230:227-237.
[9] Udomsinprasert W, Honsawek S, Poovorawan Y. Adiponectin as a novel biomarker for liver fibrosis. World J Hepatol, 2018, 10:708-718.
[10] Liu B, Xiang L, Ji J, et al. Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. J Clin Invest, 2021 131(20):e144801.
[11] Sugimoto S, Mena HA, Sansbury BE, et al. Brown adipose tissue-derived MaR2 contributes to cold-induced resolution of inflammation. Nat Metab, 2022, 4:775-790.
[12] Fuchs A, Samovski D, Smith GI, et al. Associations Among Adipose Tissue Immunology, Inflammation, Exosomes and Insulin Sensitivity in People With Obesity and Nonalcoholic Fatty Liver Disease. Gastroenterology, 2021, 161:968-981.e912.
[13] Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest , 2011, 121:2094-2101.
[14] Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet, 2016, 387:679-690.
[15] Gastaldelli A, Sabatini S, Carli F, et al. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver Int, 2021, 41:2659-2670.
[16] Hatziagelaki E, Paschou SA, Schn M, et al. NAFLD and thyroid function: pathophysiological and therapeutic considerations. Trends Endocrinol Metab, 2022, 33:755-768. |
